

To: Elizabeth Holmes[eholmes@theranos.com]
From: Sunny Balwani
Sent: Thur 6/5/2014 12:15:43 AM
Importance: Normal
Subject: FW: hCG testing
Received: Thur 6/5/2014 12:15:46 AM

From: Daniel Young
Sent: Wednesday, June 4, 2014 5:12 PM
To: Sunny Balwani; Chinmay Pangarkar
Subject: RE: hCG testing

By the way, we never switched to Immulite in LIS – it was not clear to me that this decision was made.

We are looking at the timing of switching to Immulite now as a fallback depending on the study results from today. Please let me know if this is not clear, and we can discuss. Stepping into a meeting now with Elizabeth, but will be out in a little while.

From:Sunny Balwani
Sent: Wednesday, June 04, 2014 5:06 PM
To: Daniel Young; Chinmay Pangarkar
Subject: FW: hCG testing

From: Hoda Alamdar
Sent: Wednesday, June 4, 2014 5:03 PM
To: Adam Rosendorff; CLS
Subject: RE: hCG testing

Hi Adam,

I see some results in LIS for HCG from Edison (patient: _____). The result is OORL; can we release this patient or we only release HCG from Immulite?

Thanks

Hoda

From: Adam Rosendorff
Sent: Friday, May 30, 2014 7:53 PM
To: CLS
Subject: RE: hCG testing

Correction:

From: Adam Rosendorff
Sent: Friday, May 30, 2014 7:52 PM
To: CLS
Subject: hCG testing
Importance: High

(1) ALL FURTHER HCG TESTING (CTN OR VACUTAINER) IS TO BE RUN ON THE IMMULITE

(2) HOLD ALL EDISON CTN RESULTS- DO NOT RELEASE

ADAM

Adam Rosendorff, MD, FASCP

Laboratory Director

Theranos, Inc

(650) 856-4412 (Office)

(650) 823-4953 (Mobile)

(650) 852-9594 (Fax)

arosendorff@theranos.com